Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08YFD
|
||||
| Former ID |
DIB009631
|
||||
| Drug Name |
PF-05212372
|
||||
| Synonyms |
PLA-950; Asthma therapy (inhaled, asthma), Pfizer; Asthma therapy (inhaled, asthma), Wyeth
|
||||
| Indication | Asthma [ICD10:J45] | Discontinued in Phase 1 | [1] | ||
| Company |
Wyeth
|
||||
| Target and Pathway | |||||
| Target(s) | Phospholipase A2 | Target Info | Inhibitor | [2] | |
| BioCyc Pathway | Phospholipases | ||||
| KEGG Pathway | Glycerophospholipid metabolism | ||||
| Ether lipid metabolism | |||||
| Arachidonic acid metabolism | |||||
| Linoleic acid metabolism | |||||
| alpha-Linolenic acid metabolism | |||||
| Metabolic pathways | |||||
| Ras signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Pancreatic secretion | |||||
| Fat digestion and absorption | |||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | ||||
| Reactome | Acyl chain remodelling of PC | ||||
| Acyl chain remodelling of PE | |||||
| Acyl chain remodelling of PI | |||||
| WikiPathways | Glycerophospholipid biosynthesis | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01415102) A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.. U.S. NationalInstitutes of Health. | ||||
| REF 2 | Phagedena due to leishmaniasis. Immunologic and experimental studies. Ann Dermatol Syphiligr (Paris). 1976;103(1):23-30. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.